[City, State] – [Date] – Takeda Pharmaceutical Company Limited has unveiled compelling secondary endpoint data for its investigational oral medication, zasocitinib, showcasing significant efficacy in treating plaque psoriasis (PsO) across challenging and highly impactful areas of the body. The results, presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City, demonstrate zasocitinib’s potential to offer a transformative oral treatment option for patients struggling with persistent symptoms, particularly on the scalp, palms, soles, and nails. This latest data bolsters Takeda’s confidence as it prepares to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and other regulatory bodies.
n
The new findings emerge from two pivotal Phase III clinical trials, NCT06088043 and NCT06108544, which were randomized, multi-center, double-blind studies evaluating zasocitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor. These trials enrolled adults diagnosed with moderate-to-severe plaque psoriasis. The results consistently indicated high rates of skin clearance in difficult-to-treat regions when compared to placebo, and in some instances, demonstrated superiority over existing therapies.
n
Key Efficacy in High-Impact Areas
n
The focus of this recent data release is on zasocitinib’s performance in secondary endpoints, specifically addressing psoriasis manifestations in areas that significantly impact a patient’s quality of life due to their visibility and functional impairment. These include the scalp, palms, soles, and nails.
n
Scalp Psoriasis: In the two Phase III trials, a substantial majority of patients treated with zasocitinib achieved a significant reduction in scalp psoriasis symptoms. Specifically, 77% and 74% of patients in the respective studies who had scalp psoriasis achieved a scalp-specific Physician Global Assessment (ssPGA) score of 0 or 1 (indicating clear or almost clear skin). This stands in stark contrast to the placebo groups, where only 7% and 13% of patients reached similar levels of clearance. Furthermore, zasocitinib demonstrated a clear advantage over Amgen’s Otezla (apremilast), a commonly prescribed oral therapy. At week 16, 42% and 30% of patients treated with the active comparator achieved the ssPGA 0/1 response, highlighting zasocitinib’s superior efficacy in this challenging area.
n
Palmoplantar Psoriasis: Psoriasis affecting the palms and soles can be particularly debilitating, causing pain, cracking, and difficulty with daily tasks. The data revealed that zasocitinib provided significant relief for these patients. Approximately 70% of patients with palmoplantar psoriasis treated with zasocitinib achieved a hands- and/or feet-specific Physician Global Assessment (hfPGA) score of 0 or 1 at week 16. This outcome was considerably higher than the 22% and 10% observed in the placebo groups. Again, when compared to Otezla, zasocitinib showed a notable difference, with 44% and 43% of patients in the Otezla arms achieving the hfPGA 0/1 response.
n
Nail Psoriasis: Nail involvement, often painful and aesthetically concerning, also saw significant improvement with zasocitinib. The drug demonstrated statistically significant improvements in the Nail Psoriasis Severity Index (NAPSI) compared to placebo at week 16. Importantly, these positive responses were sustained through week 24, indicating a durable effect of the treatment.
n
Chronology of Development and Data Release
n
Takeda’s journey with zasocitinib has been marked by a series of crucial milestones, culminating in the recent presentation of these promising secondary endpoint data.
n
- n
- n
December 2025: Takeda initially announced positive topline primary endpoint data from the Phase III LATITUDE PsO trials. This announcement indicated that approximately 70% of patients treated with zasocitinib achieved a static Physician Global Assessment (sPGA) of 0/1 (clear or almost clear skin) at week 16. The data also showed significantly greater Psoriasis Area and Severity Index (PASI) 75 response rates as early as week four, with continued improvement through week 24. This initial success provided a strong foundation for the subsequent detailed analyses.
n
- n
[Date of Presentation – assumed July 2026 based on image caption]: The key secondary endpoint data, focusing on high-impact areas like the scalp, palms, soles, and nails, was formally presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. This presentation provided a deeper understanding of zasocitinib’s efficacy in specific, challenging patient populations.
n
- n
[Current Fiscal Year – assumed 2026/2027]: Takeda is actively progressing towards submitting an NDA for zasocitinib to the FDA, with submissions to other global regulatory authorities also on the horizon. This strategic move is directly informed by the robust clinical data generated from the Phase III trials.
n
- n
Ongoing Research: Beyond plaque psoriasis, Takeda is exploring zasocitinib’s therapeutic potential in other inflammatory conditions. Phase III studies are underway for psoriatic arthritis, while Phase II studies are investigating its efficacy in Crohn’s disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa (HS). This broad research program underscores the potential of TYK2 inhibition as a versatile therapeutic approach.
n
- n
Head-to-Head Study Against Sotyktu: Takeda has also conducted the Phase III LATITUDE Atlas head-to-head study (NCT06973291), directly comparing zasocitinib with Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib). In this trial, zasocitinib demonstrated statistical superiority over Sotyktu in achieving a PASI 100 response rate at week 16, the primary endpoint. More than 35% of patients on zasocitinib achieved PASI 100, more than 2.5 times the response rate observed with Sotyktu. Furthermore, zasocitinib showed statistical superiority across all key secondary endpoints, including PASI 90 response and sPGA 0 at week 16.
n
n
n
n
n
n
n
Supporting Data and Clinical Significance
n
The statistical rigor and clinical significance of the presented data are paramount to understanding zasocitinib’s potential impact. The Phase III LATITUDE PsO trials employed well-established and validated outcome measures to assess treatment response.
n
- n
-
Physician Global Assessment (PGA): The PGA is a clinician-reported outcome measure that assesses the overall severity of psoriasis. A score of 0 indicates clear skin, and a score of 1 indicates almost clear skin. The ssPGA and hfPGA specifically focus on the severity of psoriasis on the scalp, and hands/feet, respectively, providing targeted assessments for these high-impact areas.
-
Psoriasis Area and Severity Index (PASI): The PASI is a widely used tool for measuring the extent and severity of psoriatic lesions across the entire body. PASI 75 and PASI 90 represent a 75% and 90% reduction in PASI score, respectively, signifying substantial disease improvement. PASI 100 indicates complete clearance of psoriasis lesions.
-
Nail Psoriasis Severity Index (NAPSI): NAPSI is a validated measure for assessing the severity of nail psoriasis, a common and often treatment-resistant manifestation of the disease.
The consistency of zasocitinib’s efficacy across these various endpoints and in different patient subgroups underscores its potential as a robust therapeutic agent. The ability to achieve significant skin clearance in hard-to-treat areas like the scalp, palms, and soles is particularly noteworthy, as these sites are often resistant to conventional therapies and significantly affect a patient’s daily functioning and self-esteem.
Dr. Leon Kircik, founder and medical director of Skin Sciences and Physicians Skin Care in Louisville, KY, and a principal investigator for the LATITUDE PsO studies, emphasized the clinical importance of these findings. "Despite advances in psoriasis care, many patients continue to experience persistent symptoms, especially in highly visible or sensitive areas like the scalp – impacting about half of patients with psoriasis – which can disproportionately affect daily life," Dr. Kircik stated. "These findings show that zasocitinib delivered consistently clear skin across the hardest-to-treat areas, including the scalp, nails, palms and soles, reinforcing its potential to become a leading oral treatment option for patients seeking meaningful, whole-body skin clearance."
Market Landscape and Competitive Positioning
The plaque psoriasis market is a dynamic and competitive landscape, currently dominated by several established therapies. Understanding zasocitinib’s position within this market requires an examination of its mechanism of action and comparison to existing treatments.
-
Current Market Leaders: Sotyktu (deucravacitinib) from Bristol Myers Squibb and Skyrizi (risankizumab) from AbbVie are currently leading the PsO market in the U.S. Sotyktu shares a similar mechanism of action with zasocitinib, as both are TYK2 inhibitors. Skyrizi, on the other hand, is an injectable monoclonal antibody that targets IL-23.
-
Zasocitinib’s Competitive Edge: As an oral TYK2 inhibitor, zasocitinib offers a convenient administration route, which is often preferred by patients over injectable therapies. The head-to-head data against Sotyktu, demonstrating superiority in PASI 100 and other key endpoints, positions zasocitinib as a potentially more effective option within the TYK2 inhibitor class. Its demonstrated efficacy in high-impact areas further differentiates it, addressing unmet needs for patients with challenging disease presentations.
-
Emerging Therapies: Johnson & Johnson (J&J) is also making a significant entry into the PsO market with its oral peptide therapy, Icotyde (icotrokinra), which received FDA approval in March 2026. Icotyde is designed to precisely block the IL-23 receptor. This new entrant, along with J&J’s existing injectable therapies Stelara (ustekinumab) and Tremfya (guselkumab), further intensifies the competition.
-
Market Projections: GlobalData forecasts a substantial growth in the PsO drug market, predicting sales to reach $11.56 billion across seven major markets (U.S., France, Germany, Italy, Spain, UK, and Japan) by 2030. This projected growth highlights the significant unmet need and the continuous demand for innovative and effective treatments.
Implications for Patients and the Future of Psoriasis Treatment
The positive data from Takeda’s Phase III trials for zasocitinib carry significant implications for patients living with plaque psoriasis and the broader field of dermatological treatment.
-
Addressing Unmet Needs: For the millions of individuals worldwide affected by psoriasis, particularly those whose disease is severe or located in difficult-to-treat areas, zasocitinib offers a beacon of hope. The drug’s ability to achieve substantial skin clearance on the scalp, palms, and soles can lead to improved physical comfort, reduced pain, enhanced daily functioning, and a significant boost in self-confidence and overall quality of life.
-
The Rise of Oral Therapies: The development and potential approval of oral treatments like zasocitinib represent a paradigm shift in psoriasis management. Oral medications offer convenience and accessibility, potentially reducing the burden of self-injection and improving patient adherence to treatment.
-
Precision Medicine in Psoriasis: As our understanding of the immune pathways involved in psoriasis deepens, therapies like TYK2 inhibitors are emerging as more targeted and precise treatment options. The success of zasocitinib, along with the ongoing research into its application for other inflammatory conditions, suggests a future where personalized and highly effective treatments are available for a wider range of immune-mediated diseases.
-
Advancements in Psoriatic Arthritis and Other Conditions: The ongoing Phase III studies for psoriatic arthritis and Phase II studies for Crohn’s disease, ulcerative colitis, vitiligo, and HS indicate that the therapeutic potential of TYK2 inhibition may extend far beyond plaque psoriasis. This broad exploration suggests that zasocitinib, if approved, could become a significant asset in Takeda’s portfolio and a valuable tool for treating a spectrum of inflammatory disorders.
Psoriasis, a chronic, systemic immune-mediated inflammatory disease, is characterized by itchy, painful, disfiguring, and disabling skin lesions. Globally, an estimated 64 million people live with psoriasis, with plaque psoriasis (PsO) accounting for approximately 80%-90% of these cases. The disease profoundly impacts individuals’ physical, emotional, and psychological well-being.
With the forthcoming NDA submission, the medical community and patient advocacy groups will be closely watching for regulatory decisions on zasocitinib. The promising efficacy demonstrated in high-impact areas, coupled with the convenience of an oral formulation and favorable comparisons to existing treatments, positions zasocitinib as a strong contender to become a vital new option in the evolving landscape of psoriasis management.
